Bernstein Sticks to Its Buy Rating for Centene (CNC)
Bernstein analyst Lance Wilkes maintained a Buy rating on Centene today and set a price target of $48.00.
Easter Sale - 70% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to TipRanks, Wilkes is an analyst with an average return of -8.7% and a 32.67% success rate. Wilkes covers the Healthcare sector, focusing on stocks such as Centene, Cigna, and HCA Healthcare.
In addition to Bernstein, Centene also received a Buy from Barclays’s Andrew Mok CFA in a report issued yesterday. However, today, TipRanks – xAI reiterated a Hold rating on Centene (NYSE: CNC).
Based on Centene’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $49.73 billion and a GAAP net loss of $1.1 billion. In comparison, last year the company earned a revenue of $40.81 billion and had a net profit of $283 million
Read More on CNC:
Disclaimer & DisclosureReport an Issue
- Midday Fly By: Health insurers get ‘positive surprise’ from CMS
- Deutsche sees margin pressure despite ‘positive surprise’ from CMS
- Centene price target raised to $34 from $32 at BofA
- Closing Bell Movers: Health insurers rise on higher Medicare rate hike
- CMS finalizes 2027 Medicare Advantage payments with 2.48% increase
